top of page

Biopharma Daily Stock Updates - 11/15/21

$XBI $123.89 -2.1%

 

Covid Updates

$MRNA +1.7% Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older. source


$NVAX +1.5% Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373. source


$RDHL -7.4% RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients. source



Pipeline Updates

$AMRN -2.0% AMARIN REPORTS SUBGROUP DATA FROM REDUCE-IT® HIGHLIGHTING BENEFITS OF VASCEPA®/VAZKEPA (ICOSAPENT ETHYL) IN PATIENTS WITH PRIOR PERIPHERAL ARTERY DISEASE (PAD) PRESENTED IN RAPID FIRE ORAL SESSION PRESENTATION AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC source


$KZR +2.7% Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis source


$ARWR -10.9% Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection source


$PHAS -18.4% PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding source


$GLPG 0.0% Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis. source


$MRNA +1.7% Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery. source


$CHRS +1.6% Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer. source


$APVO -16.5% Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting. source


$ICPT -7.2% Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC. source


$CBAY -2.7% CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC. source


$RYTM +0.5% Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome. source


$CYTK 0.0% Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021. source


$IFRX -12.2% InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV). source


$ARWR -10.9% Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021. source


$INZY +0.1% Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency. source


$MIST +8.0% Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT. source


$PTGX -3.7% Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis. source


$GLYC +0.5% GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML). source


$RCKT -23.7% Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease. source


$OYST -6.7% Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray. source


$ERYP +3.7% ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting. source


$IOVA -7.0% Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting. source


$NXTC -3.9% NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting. source


$EYPT +2.1% EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD. source


$OTLK -4.9% Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference. source



Business Updates

$APLS -3.3% Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock source

 

Posted by FS/JM

0 comments
bottom of page